IL42317A - Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazine - Google Patents
Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazineInfo
- Publication number
- IL42317A IL42317A IL42317A IL4231773A IL42317A IL 42317 A IL42317 A IL 42317A IL 42317 A IL42317 A IL 42317A IL 4231773 A IL4231773 A IL 4231773A IL 42317 A IL42317 A IL 42317A
- Authority
- IL
- Israel
- Prior art keywords
- seryl
- hydrazine
- trihydroxybenzyl
- hydroxytryptophan
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (6)
1. A pharmaceutical preparation which is active against depressions and insomnia containing L-5-hydroxytryptophan or a pharmaceutically acceptable salt thereof and ^-(D.L-seryl)-N^-(2 ,3 ,4-trihydroxybenzyl) -hydrazine or a pharmaceutically acceptable salt thereof in amounts which correspond to a weight ratio between L-5-hydroxytryptophan and ^-(D,L-seryl)- 2, 3» -trihydroxybenzyl) -hydrazine of about 1:5 to about 2:1.
2. A pharmaceutical preparation according to claim 1 in the form of a finished dosage form suitable for enteral administration and containing per dosage unit about 25 mg to about 250 mg of L-5-hydrox tryptophan or an equivalent amount of a pharmaceutically acceptable salt thereof and about 25 mg to about 250 mg of N1-(D,L-seryl)- 2-(2,3,4-trihydroxy-benzyl)-hydrazine or an equivalent amount of a pharmaceutically acceptable salt thereof.
3. A process for the manufacture of a pharmaceutical preparation which is active against depressions and insomnia which process comprises mixing L-5-hydroxytryptophan or a pharmaceutically acceptable salt thereof with N^-CD^L-seryl)- N -( 2, 3 ,4-trihydroxybenzyl)-hydrazine or a pharmaceutically acceptable salt thereof in amounts which correspond to a weight ratio between L-5-hydroxytryptophan and N^-(D,L-seryl)- 2, , 4-trihydroxybenzyl)-hydrazine of about 1:5 to about 42317/2 r 2:1.
4. A process according to claim 3» wherein there is manufactured a finished dosage form suitable for enteral administration, said dosage form containing per dosage unit about 25 mg to about 250 mg of L-5-hydroxytryptophan or an equivalent amount of a pharmaceutically acceptable salt thereof and about 25 mg to about 250 mg of N^-CD.L-seryl)-N -(2 ,3 ,4-trihydroxybenzyl) -hydrazine or an equivalent amount of a pharmaceutically acceptable salt thereof.
5. A process for the manufacture of a pharmaceutical preparation as claimed in claim 1, substantially as hereinbefore described with reference to the Examples.
6. A pharmaceutical preparation as claimed in claim 1, when manufactured by the process claimed in claim 3» claim 4 or claim 5 ·
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH984672 | 1972-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42317A0 IL42317A0 (en) | 1973-07-30 |
| IL42317A true IL42317A (en) | 1976-04-30 |
Family
ID=4356299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42317A IL42317A (en) | 1972-06-30 | 1973-05-21 | Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazine |
Country Status (18)
| Country | Link |
|---|---|
| AT (1) | AT338412B (en) |
| AU (1) | AU476456B2 (en) |
| BE (1) | BE801645A (en) |
| CA (1) | CA1015272A (en) |
| DD (1) | DD107592A5 (en) |
| DE (1) | DE2327636A1 (en) |
| ES (1) | ES416383A1 (en) |
| FR (1) | FR2190453B1 (en) |
| GB (1) | GB1369189A (en) |
| HU (1) | HU167292B (en) |
| IE (1) | IE37833B1 (en) |
| IL (1) | IL42317A (en) |
| LU (1) | LU67898A1 (en) |
| NL (1) | NL7308435A (en) |
| PH (1) | PH9584A (en) |
| SE (1) | SE407744B (en) |
| SU (1) | SU533323A3 (en) |
| ZA (1) | ZA733284B (en) |
-
1973
- 1973-05-15 ZA ZA733284A patent/ZA733284B/en unknown
- 1973-05-18 AU AU55897/73A patent/AU476456B2/en not_active Expired
- 1973-05-21 IL IL42317A patent/IL42317A/en unknown
- 1973-05-30 DE DE19732327636 patent/DE2327636A1/en active Pending
- 1973-06-18 NL NL7308435A patent/NL7308435A/xx not_active Application Discontinuation
- 1973-06-22 IE IE1034/72A patent/IE37833B1/en unknown
- 1973-06-27 FR FR7323456A patent/FR2190453B1/fr not_active Expired
- 1973-06-28 SU SU1940152A patent/SU533323A3/en active
- 1973-06-28 CA CA175,140A patent/CA1015272A/en not_active Expired
- 1973-06-28 ES ES416383A patent/ES416383A1/en not_active Expired
- 1973-06-28 LU LU67898A patent/LU67898A1/xx unknown
- 1973-06-28 PH PH14782*UA patent/PH9584A/en unknown
- 1973-06-29 HU HUHO1588A patent/HU167292B/hu unknown
- 1973-06-29 BE BE132885A patent/BE801645A/en unknown
- 1973-06-29 GB GB3107173A patent/GB1369189A/en not_active Expired
- 1973-06-29 SE SE7309254A patent/SE407744B/en unknown
- 1973-06-29 DD DD171943A patent/DD107592A5/xx unknown
- 1973-06-29 AT AT574273A patent/AT338412B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE37833B1 (en) | 1977-10-26 |
| FR2190453A1 (en) | 1974-02-01 |
| PH9584A (en) | 1976-01-19 |
| NL7308435A (en) | 1974-01-02 |
| ES416383A1 (en) | 1976-02-16 |
| IL42317A0 (en) | 1973-07-30 |
| AT338412B (en) | 1977-08-25 |
| IE37833L (en) | 1973-12-30 |
| GB1369189A (en) | 1974-10-02 |
| LU67898A1 (en) | 1975-04-11 |
| BE801645A (en) | 1974-01-02 |
| HU167292B (en) | 1975-09-27 |
| AU476456B2 (en) | 1976-09-23 |
| DD107592A5 (en) | 1974-08-12 |
| CA1015272A (en) | 1977-08-09 |
| FR2190453B1 (en) | 1976-04-09 |
| ATA574273A (en) | 1976-12-15 |
| SE407744B (en) | 1979-04-23 |
| AU5589773A (en) | 1974-11-21 |
| DE2327636A1 (en) | 1974-01-17 |
| SU533323A3 (en) | 1976-10-25 |
| ZA733284B (en) | 1974-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1274402B1 (en) | Pharmaceutical composition for the controlled release of paracetamol | |
| HU178867B (en) | Process for preparing synergetic analgetic composition containing nalbuphine and acetaminophene | |
| HU892559D0 (en) | Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient | |
| JPH02270820A (en) | Slowly releasable ethodrug | |
| ES2240033T5 (en) | Trimetazidine extended-release matrix tablet after oral administration | |
| HUP0105173A2 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| JPS6357405B2 (en) | ||
| CA1182049A (en) | Apap antacid composition | |
| GB1487334A (en) | Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof | |
| TW372193B (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient | |
| IL43820A (en) | Pharmaceutical compositions for treatment of spastically disabled human beings containing bronchodilating sympathomimetic amines | |
| IL42317A (en) | Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazine | |
| US2427887A (en) | Analgesic composition | |
| PT891186E (en) | Nasal administration of agents for treatment of delayed onset emesis | |
| US2906665A (en) | L-amphetamine alginate | |
| JPS6092214A (en) | Composition for filling soft capsule | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| GB1464467A (en) | Pharmaceutical composition for the treatment of coronary | |
| US3777026A (en) | N-substituted amino-n-nitroso-amino-acetonitriles as anti-anginal agents | |
| IE37288B1 (en) | Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children | |
| IL29570A (en) | Compositions for the treatment of glaucoma containing 5,10-epoxy-5h-dibenzo(a,d)cycloheptene derivatives | |
| JPS61200913A (en) | Carcinostatic agent | |
| JPH0113449B2 (en) | ||
| GB1375806A (en) | ||
| RU2150273C1 (en) | Antihypoxic and actoprotective agent |